Nestle divests peanut allergy business Palforzia ZURICH (Reuters) – Nestle has divested its peanut allergy treatment business Palforzia, the Swiss food company… Read More

Source: Adrian Day  (10/4/23)  Global Analyst Adrian Day looks at why gold has fallen and suggests it may have further to go. Meanwhile, he takes a look at some gold stocks… Read More

Toddlers with severe peanut allergies may benefit from a brand new, experimental skin patch that prepares their bodies for any possible accidents. As you may already know, one of the most pr… Read More

An anonymous reader quotes a report from Bloomberg: When Nestle SA's peanut allergy medicine first hit the market in 2020, Robert Wood, the director of pediatric allergy at Johns Hopkins Hos… Read More

Food giant Nestlé has acquired a 49.95 percent stake in Yfood, a direct-to-consumer (DTC) startup that produces meal replacement beverages, powders and nutrition bars. The deal values… Read More

Food giant Nestlé put its Palforzia peanut allergy treatment up for sale only two years after acquiring the company that developed it for $2.6 billion. The move comes after slower tha… Read More

ICER Weekly View View as Webpage Sign up for ICER's Weekly View Newsletter   Weekly View December 2, 2022 From the desk of Priya Ranad… Read More

(Bloomberg) -- Nestle SA agreed to buy Aimmune Therapeutics Inc. for $2.6 billion, adding a promising peanut allergy treatment to its portfolio of coffee, snacks and water. Aimmune makes a… Read More

China Moves to Interfere With TikTok Sale Nestle Stocks Up on Peanut Allergy Treatment FAA Approves Amazon Delivery Drones The Fed’s New Strategy  BUSINESS  China Moves to I… Read More